TP53 and cancer: In a plethora of other proteins and enzymes, RES inhibited cell viability via PLA2 decrease and sensitized breast cancer cells to doxorubicin therapy [163] or lead to p53-mediated cell death of prostate LNCAP cancer cells [164].